Patent and Tradem

Attorney Docket Number

FID/SB/08A (10-96) r use through 10/31/99. OMB 0651-0031 le: U.S. DEPARTMENT OF COMMERCE

s it contains a valid OMB control number

sons are required to respond to a collection of information Under the Paperwork Reduction Act of 1995

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of A Sheet

Complete if Known **Application Number** 07/18/2001 Filing Date R. Rex Denton First Named Inventor Group Art Unit **Examiner Name**

MWH-008US

				U.S. PATENT DOCL	JMENTS	Pages, Columns, Lines,
xaminer nitials	Cite No.1	Number	ocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	AA	5,625,039	A	Washida et al.	04/29/1997	col. 5, line 10 - col. 9, line 13 col. 6, line 49-col.7, line 2; col 13, line 13
	AB	5,770,396	A	Kinet et al.	06/23/1998	col. 6, line 49-col. 7, line 2, col 15, line 21 col. 26, line 21-col. 27.
	100	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				line 3; col. 30, line 44 - col. 31, line
						61; col. 32, line 41-54
						01, con 32,
	ļ					
	 					
	+					
	+					
	+					+

				FOF	REIGN PATENT DOCUMEN	TS	Pages, Columns, Lines,	Т
Examiner		Foreign Patent Docu		Cument Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T
Initials*	No.1	Office:	95/05481		Isis Innovation Limited	02/23/1995	pages 7-16	+
	AC	WO	75/05-101					+
		ļ						+
							 	╁
								1
	<u> </u>	1_						_

	Date
Examiner	Considered
Signature	Draw line through citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box -
Under the Paperwork Reduction Act of 1995

PTO/SB/08B (10-96) use through 10/31/99. OMB 0651-0031 U.S. DEPARTMENT OF COMMERCE it contains a valid OMB control number.

Appro Patent and Tradema ons are required to respond to a collection of information Complete if Known

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

07/18/2001 Filing Date R. Rex Denton First Named Inventor Group Art Unit

Application Number

(use as many sheets as necessary) of 3

Examiner Name Attorney Docket Number MWH-008US

.6/			
THE STATE OF THE S		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	Τ-
FRADE Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	ADAMCZEWSKI, M. ET AL, "Expression and Biological Effects of High Levels of Serum IgE in Epsilon Heavy Chain Transgenic Mice.," European Journal of Immunology, Vol. 21, p. 617-626, (1991).	-
		COX, H.E. ET AL., , "Association of Atopic Dermatitis to the Beta Subunit of the High Affinity	
		Immunoglobulin E Receptor, British Journal of Definition of Distinct Human Secreted IgE DIAZ-SANCHEZ, A.S. ET AL., "Regulation of the Expression of Distinct Human Secreted IgE Proteins Prodouced by Alternative RNA Splicing" in Immunological Intervention Strategies in Allergy Biochemical Society Transactions, Vol. 25, (No. 25) p. 383-387, (1997).	
		TOYGON BYHLLIB W. ET AL "Mutational Analysis of the High Affinity Immunoglobulin	
		E Receptor B Subunit Gene in Asthma," Thorax, Vol. 54, p. 409-412, (1999). HILL AND COOKSON, "A New Variant of the B Subunit of the High-Affinitiy Receptor for Immunoglobulin E (FCER1-B E237G): Associations with Measures of Atopy and Bronchial	
		Hyper-Responsiveness," Human Molecular Genetics, vol. 3, p. 355 Jos., The HIZAWA, NOBUYUKI ET AL., "A Common FCER1B Gene Promoter Polymorphism Influences Total Serus IgE Levels in a Japanese Population," Am J Respi Crit Care Med, Vol.	
		KINET, J.P. ET AL., "Isolation and Characterization of cDNA's Coding for the B-Subunit of the High-Affinity Receptor for Immunoglobulin E. Proceedings of the National Academy of	
		Sciences," PNAS, Vol. 85, p. 6483-6487, (1998). PALMER, L.J. ET AL., "FCER1-B Polymorpohisms and Total Serum 1gE Levels in Endemically Parasitized Australian Aborigines," Am. J. Hum. Genet., Vol. 61, p. 182-188,	
		RIVERA, J. ET AL, "Studies with a Monoclonal Antibody to the BSubunit of the Receptor with High Affinitiy for Immunglobulin E," Molecular Immunology, Vol. 25 (No. 7), p. 547-661,	1
		SATO, T. ET AL., "A New Method for Studying the Binding of Human IgE to CD23 and the Inhibition of this Binding," Journal of Immunological Methods, Vol. 209, p. 59-66, U (1997).	ıd
		SHIRAKAWA, TARO ET AL., "Association between Atopy and Variants of the B Subunit of the High-Affinity Immunoglobulin E Receptor," Nature Genetics, Vol. 7, p. K 125-130, (1994).	

	Date
Examiner	Considered
Signature	the ward election if not in conformance and no

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please	type :	a olus	sion	(+)	inside	this	box	_
1 10030	type .	a pius	aigii	1.1	1113146	41110	OOA	

Under the Paperwork Reduction Act of 1995

Approx Patent and Tradema

PTO/SB/08B (10-96)
use through 10/31/99 OMB 0651-0031
a: U.S. DEPARTMENT OF COMMERCE

it contains a valid OMB control number. ons are required to respond to a collection of information

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of 5

Complete if Known				
Application Number				
Filing Date	07/18/2001			
First Named Inventor	R. Rex Denton			
Group Art Unit				
Examiner Name				
Attorney Docket Number	MWH-008LIS			

Sheet OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T2 xeminer Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 publisher, city and/or country where published. SHIRAKAWA, T. ET AL., "Association between Atopic Asthma and a Coding Variant of FCER1B in a Japanese Popoulation," Human Molecular Genetics, Vol. 5, p. 1129-1130, (1996). ΒI WITTHUHN B. A.. ET AL., "Isolation and Characterization of the Rat B-Subunit Gene of the High Affinity Receptor for Immunoglobulin E.," Molecular Immunology, Vol. 33, (No. 10), p. BM|881-890

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.